Publications by authors named "Mathilde Marchand"

Claim this Profile
S
Secondary alveolar bone grafting of clefts using bioactive glass 45S5: Long-term dental and periodontal status.
Emmanuelle Verdier, Olivier Azzis, Mathilde Marchand, Sylvie Jeanne, Ronan Lebullenger

Am J Orthod Dentofacial Orthop· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of Zinc-Based Metal-Organic Framework ZIF-8 on Paper: A Pilot Study on Visual Appearance and Effectiveness.
Eleonora Balliana, Mathilde Marchand, Valentina Di Matteo, Barbara Ballarin, Maria Cristina Cassani

Polymers (Basel)· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetics and Exposure-Response of Subcutaneous Atezolizumab in Patients With Non-Small Cell Lung Cancer.
Phyllis Chan, Stephanie N Liu, Nathalie Gosselin, Zacharie Sauve, Mathilde Marchand

CPT Pharmacometrics Syst Pharmacol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psychological evaluation of candidates for the uterus transplantation French trial.
Léa Karpel, Margaux Nicaise, Marie Carbonnel, Mathilde Le Marchand, Catherine Racowsky

Acta Obstet Gynecol Scand· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First Longitudinal Analysis of the Immunological Mechanism at Play in Uterus Transplantation.
Marie Carbonnel, Remy Villette, Maxime Petit, Nadine Tarantino, Veronique Morin, Mathilde Le Marchand

Transplant Direct· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor growth and overall survival modeling to support decision making in phase Ib/II trials: A comparison of the joint and two-stage approaches.
Mathilde Marchand, Antonio Gonçalves, François Mercier, Pascal Chanu, Jin Y Jin

CPT Pharmacometrics Syst Pharmacol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.
Brendan Bender, Chi-Chung Li, Mathilde Marchand, David C Turner, Feifei Li

Clin Transl Sci· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of two-stage and joint TGI-OS modeling using data from six atezolizumab clinical studies in patients with metastatic non-small cell lung cancer.
Antonio Gonçalves, Mathilde Marchand, Phyllis Chan, Jin Y Jin, Jérémie Guedj

CPT Pharmacometrics Syst Pharmacol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li

Clin Cancer Res· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework.
Colby S Shemesh, Phyllis Chan, Mathilde Marchand, Antonio Gonçalves, Shweta Vadhavkar

Clin Pharmacol Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.
René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li

Clin Cancer Res· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tocilizumab-treated convalescent COVID-19 patients retain the cross-neutralization potential against SARS-CoV-2 variants.
Camille Chauvin, Laurine Levillayer, Mathilde Roumier, Hubert Nielly, Claude Roth, Mathilde Le Marchand

iScience· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Extension of the Alternative Intravenous Dosing Regimens of Atezolizumab into Combination Settings through Modeling and Simulation.
Stephanie N Liu, Mathilde Marchand, Xiaoyan Liu, Gladys Ingle, Vidya Maiya

J Clin Pharmacol· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of COVID-19 on Subclinical Placental Thrombosis and Maternal Thrombotic Factors.
Marie Carbonnel, Camille Daclin, Morgan Tourne, Emmanuel Roux, Mathilde Le-Marchand

J Clin Med· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: Post-Partum SARS-CoV-2 Infection After the First French Uterus Transplantation.
Jean Marc Ayoubi, Marie Carbonnel, Niclas Kvarnström, Aurelie Revaux, Marine Poulain, Mathilde Le Marchand

Front Surg· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study.
Kenta Yoshida, Phyllis Chan, Mathilde Marchand, Rong Zhang, Benjamin Wu

AAPS J· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Results of a Dose-Finding Phase 1b Study of Subcutaneous Atezolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.
Enriqueta Felip, Mauricio Burotto, Zanete Zvirbule, Luis A Herraez-Baranda, Pascal Chanu, Mathilde Marchand

Clin Pharmacol Drug Dev· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of overall survival in patients across solid tumors following atezolizumab treatments: A tumor growth inhibition-overall survival modeling framework.
Phyllis Chan, Mathilde Marchand, Kenta Yoshida, Shweta Vadhavkar, Nina Wang

CPT Pharmacometrics Syst Pharmacol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-dependent population PK models of single-agent atezolizumab in patients with cancer.
Mathilde Marchand, Rong Zhang, Phyllis Chan, Valerie Quarmby, Marcus Ballinger

Cancer Chemother Pharmacol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
Kari M Morrissey, Mathilde Marchand, Hina Patel, Rong Zhang, Benjamin Wu

Cancer Chemother Pharmacol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nicotine Population Pharmacokinetics in Healthy Adult Smokers: A Retrospective Analysis.
Mathilde Marchand, Patrick Brossard, Henri Merdjan, Nicola Lama, Rolf Weitkunat

Eur J Drug Metab Pharmacokinet· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of bevacizumab in cancer patients with external validation.
Kelong Han, Thomas Peyret, Mathilde Marchand, Angelica Quartino, Nathalie H Gosselin

Cancer Chemother Pharmacol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors.
Kelong Han, Jin Y Jin, Mathilde Marchand, Stephen Eppler, Nicholas Choong

Cancer Chemother Pharmacol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis